Vaccitech will present topline data from the APOLLO clinical trial at the 35th Annual International Papillomavirus Conference, IPVC. The APOLLO trial is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus, HPV, infection. The data will be presented as a poster at IPVC in Washington, D.C. on Thursday, April 20, 2023 at 2 PM EDT, by Dr. Meg Marshall, Chief Medical Officer of Vaccitech. "The safety and immunogenicity data presented at IPVC shows the potential of VTP-200 in treating persistent high-risk HPV infections. Currently, women with persistent HPV infections have no treatment options until they develop high grade lesions," said Meg Marshall, CMO of Vaccitech. "We believe VTP-200 has the potential to address a serious unmet need and look forward to sharing the results of the final analysis, to include data on clearance of infection and cervical lesions, in 2024."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VACC:
- Vaccitech : Phase 1b/2a trial of VTP-300 met primary, secondary endpoints
- Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
- Vaccitech price target lowered to $15 from $20 at H.C. Wainwright
- Vaccitech price target lowered to $7 from $23 at Barclays
- Vaccitech reports 2022 EPS 14c vs. ($1.96) last year
